Insights & news

European General Court Dismisses Medicines Dual Pricing Complaint Thus Allowing GSK To Avoid New Probe

  • 27/09/2018
  • Articles

The European General Court (“GC”) dismissed on 26 September 2018 a 1999 complaint filed by EAEPC, the industry association of parallel traders in medicines, that had urged the European Commission (the “Commission”) to resume its investigation of a “dual pricing” scheme operated by GlaxoSmithKline (“GSK”) in Spain. Under the scheme, the prices which GSK charged to wholesalers differed depending on whether the medicines were resold in Spain under regulated prices or were exported abroad free from pricing constraints.
 
GSK had been the subject of a Commission competition procedure which in 2009 had resulted in a verdict of the Court of Justice of the European Union (“ECJ”) that the dual pricing scheme had as its object the restriction of competition and thus infringed Article 101 (1), Treaty on the Functioning of the European Union (“TFEU”). The ECJ went on to declare that the Commission had not carried out a full examination of the arguments put forward by GSK in favour of an exemption of the scheme pursuant to Article 101 (3), TFEU.
 
Following the ECJ’s judgment, the Commission started its analysis of the scheme under Article 101 (3), TFEU and in 2012 also opened an investigation of alleged dual pricing practices in Spain by other firms. But in May 2014 the Commission decided to reject the 1999 complaint for lack of a sufficient Union interest in a continued investigation of the alleged competition law infringements. This is because (i) GSK’s conduct under scrutiny had ceased many years ago; (ii) that conduct did not produce enduring effects; and (iii) the case had been handled by national competition authorities and courts as well.
 
As noted, the EAEPC took steps to have the inquiry against GSK re-opened, but the GC has now confirmed the rejection of the complaint. EAEPC immediately indicated that it would consider filing an appeal to the ECJ.

Before the GC, the EAEPC challenged the Commission’s findings as inconclusive, questioned the absence of sufficient Union interest and characterised the reasoning underlying the decision as flawed.

In response, the GC considered that the EAEPC had failed to adduce evidence disproving the Commission’s findings.

It furthermore noted that the Commission had broad discretion in determining a matter to be in the Union interest. While the case may bear a “special feature” due to a Commission decision that was subject to two European judgments adopted by the ECJ and the GC, the GC noted that the ‘special feature’ evoked by EAEPC does not prevent the Commission from concluding that there is no sufficient Union interest based on the Commission’s three considerations cited earlier.

By the same token, the GC also rejected EAEPC’s position that the Commission failed to examine and state reasons for its conclusion, as the Commission’s decision clearly indicates that the disputed dual pricing scheme had been suspended and that GSK had refrained from implementing it.

Lastly, the GC stressed that the rejection of the complaint was not tantamount to an authorisation of export restrictions in Spain. It supported the Commission’s position that “the fact of not adopting a decision on an infringement cannot in itself be determinative of the self-assessment carried out by the undertakings under Article 101 (3), TFEU”. The GC specified that self-assessment should be based on current market conditions and not on a decision rejecting a complaint for lack of Union interest in a specific historical context.

The ECJ’s judgment is available at this link.

Key contacts

Related practice areas

Related insights

Sign up for updates
    • 12/03/2019
    • Articles

    Belgium – New legislation in the making on cannabis for medical use

    In light of the growing international scientific consensus on the positive medicinal effects of cannabis, Belgian lawmakers have tabled proposed legislation which, if adopted, would make the use of cannabis for medical purposes legal. A Cannabis Office will be created within the Federal Agency for Medicines and Health Products which will be in charge of the legal production of medical cannabis, establishing a monopoly for the Belgian State on the cultivation, trade, import and export of that product. Other EU member states already have followed a similar legislative route (e.g. the Netherlands). Following the establishment of the Cannabis Office, a call for tenders will be issued for the cultivation of a certain amount of cannabis. Licences will be granted to the successful applicants to cultivate cannabis in specified locations. The Cannabis Office will purchase the harvest and export and/or distribute it. The manufacturing process will be subject to stringent standards. For example, the cannabis will need to have a stable concentration of the active substance as well as a stable ratio of the main active ingredients, i.e. cannabidiol (CBD) and the main psychoactive compound tetrahydrocannabinol (THC). The move comes more than three years after the first cannabis-based medicine (Sativex spray) became authorized and reimbursable in Belgium for certain multiple sclerosis (“MS”) patients. If physicians want to prescribe medicinal cannabis to their patients for pain relief, or the treatment of nausea and reduced appetite during chemotherapy, further regulatory changes will be required.

    Read more
    • 08/03/2019
    • Articles

    Belgium - Bill Tackles Medicine Shortages

    A number of members of parliament introduced last week a private members’ bill that has the twin objectives of tackling medicine shortages and combating the trade in falsified medicines (bill 54 3599/001 – the “Bill” – see attached). Medicine Shortages The Bill will modify the Law of 25 March 1964 to (i) allow the concept of “temporary cessation of supply of medicines” to be determined by Royal Decree; (ii) allow the Minister to make recommendations of suitable therapeutical alternatives in case of temporary shortages of specific medicines; (iii) preclude wholesalers (“WS”) with a public-service WS status from supplying ordinary WS; and (iv) impose particular shortage-related obligations on parallel traders which previously only applied to the marketing authorisation holders. The proposed ban on public-service WS to supply ordinary WS (and therefore limit their supplies to, broadly, other public-service WS, pharmacists and hospitals) is designed to ensure the steady supply of medicines to the local market and, conversely, cut down on exports that threaten public health. Under specific conditions, the ban will not apply to medicines earmarked for clinical trials. Falsified Medicines The Bill establishes criminal sanctions for specific violations of Regulation 2016/161 which lays down safety features for the packaging of medicines for human use. The current caretaker government no longer commands a majority in the federal Chamber of Representatives. However, the Bill may be assured of an ad hoc majority in that it has already been given a time slot in the session of the committee for public health scheduled on 12 March 2019.

    Read more
    • 04/03/2019
    • Articles

    Belgian Competition Authority Will Again Focus on Pharmaceuticals in 2019

    On 1 March 2019, the Belgian Competition Authority published its yearly policy note setting out its enforcement priorities for the year (see attachments). As was the case in previous years, the pharmaceutical sector is one of the BCA’s main targets for action. Once more, the BCA indicates that it deliberately emulates the approach of other national competition authorities in focusing on “all links of the value chain, including prices charged by pharmaceutical firms, competition between distributors with public-service obligations, the competitive dynamics and innovation at the pharmacy level”. Given the pending inquiries in the sector, this announcement again does not come as a surprise. It also reflects the general competition scrutiny of the sector in Europe, as was evidenced by the publication in January 2019 of the Competition Pharmaceutical Enforcement Report by the European Commission (see, Van Bael & Bellis Life Sciences Newsflash of 28 January 2019). In other news relevant to the sector, the BCA also confirms its continued attention to public procurement. Apart from the pharmaceutical sector, the BCA will target telecommunications, distribution, service providers and logistics. All in all, this year’s enforcement priorities closely resemble those applying in 2018.

    Read more

Subscribe to our updates

Please select the practice areas you are interested in: *